[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100550898":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":27,"responsibleParty":44,"collaborators":11,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":11,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":11,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":11,"overallStatus":30,"whyStopped":11,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Grit Biotechnology","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"GT307 injection treatment group","EXPERIMENTAL",null,[13],"Biological: GT307 injection",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"BIOLOGICAL","GT307 injection","GT307 injection to treat solid tumours",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":26},"Kang Yu, PHD","CONTACT","+86 （021）63455050","8571","kangyu1489@fckyy.org.cn",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Obstetrics & Gynecology Hospital of Fudan University","RECRUITING","Shanghai","Shanghai Municipality","200011","China","CN",{"type":37,"coordinates":38},"Point",[39,40],121.45806,31.22222,{"lat":40,"lon":39},[43],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":26},{"type":45,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100550898","autologous-tumor-infiltrating-lymphocyte-gt307-for-treatment-of-patients-with-solid-tumours-100550898",false,"NCT06453057","Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Solid Tumours","A Single-arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Solid Tumours","Inclusion Criteria:\n\n* 1\\. Voluntarily join the study, signed informed consent form， willing and able to comply with the study protocol;\n* 2\\. Age 18 to 70 years old;\n* 3\\. Ovarian cancer that progresses after recurrence or first-line chemotherapy；\n* 4\\. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;\n* 5\\. Expected survival time of ≥ 12 weeks;\n* 6\\. Good function of vital organs;\n* 7\\. Subjects entering this study due to disease progression must have an imaging record of disease progression before tumor sampling;\n* 8\\. At least one measurable target lesion that meets the definition of RECIST v1.1 after tumor sampling.\n\nExclusion Criteria:\n\n* 1.Patients with uncontrollable tumor-related pain as judged by the investigator; participants requiring analgesic medication must already have a stable analgesic regimen at the time of study entry; symptomatic lesions suitable for palliative radiotherapy should be completed prior to study entry;\n* 2.Known mental illness, alcoholism, drug use or substance abuse;\n* 3.Pregnant or lactating women; or women who are pregnant, breastfeeding, or planning to become pregnant within 1 year after cell infusion;\n* 4.Those who have received other clinical trial drug treatment within 4 weeks before preconditioning by lymphodepletion,plan to participate in other clinical trial drug treatment during the study;\n* 5.The investigators determine that other conditions that make the patient not suitable for enrollment.","ALL","18 Years","70 Years",{"count":57,"type":58},18,"ESTIMATED","INTERVENTIONAL",[61],"NA","This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT307) for treatment of patients with solid tumours,while evaluating pharmacokinetic characteristics and efficacy assessment to determine the optimal biological dose (OBD).",[64],"Adult","2026-04-13",{"date":67,"type":68},"2026-04-14","ACTUAL",{"date":70,"type":68},"2024-07-04",{"date":72,"type":58},"2027-06-06",{"name":5,"class":6},1]